Alvotech ALVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alvotech Shares Rise After FDA Okays Simlandi Manufacturing Process
-
Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch
-
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
-
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
-
Alvotech Shares Rise After FDA Approves Additional Manufacturing for Simlandi
-
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
-
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
-
Alvotech to present at upcoming investor conferences in September
Trading Information
- Previous Close Price
- ISK 562.00
- Day Range
- ISK 560.00–564.00
- 52-Week Range
- ISK 364.00–1,045.00
- Bid/Ask
- ISK 560.00 / ISK 564.00
- Shares Outstanding
- 356.82M
- Market Cap
- ISK 201.24B
- Volume/Avg
- 3,052 / 158,868
Key Statistics
- Price/Earnings (Normalized)
- 43.54
- Price/Sales
- 2.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,460
- Website
- https://www.alvotech.com
Valuation
|
Metric
|
ALVO
|
|---|---|
Price/Earnings (Normalized) | 43.54 |
Price/Book Value | — |
Price/Sales | 2.70 |
Price/Cash Flow | — |
Price/Earnings
ALVO
Financial Strength
|
Metric
|
ALVO
|
|---|---|
Quick Ratio | 0.83 |
Current Ratio | 1.65 |
Interest Coverage | 0.75 |
Quick Ratio
ALVO
Profitability
|
Metric
|
ALVO
|
|---|---|
Return on Assets (Normalized) | −11.60% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −4.50% |
Return on Assets
ALVO
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|#!p!z%x | LOCK|<JdS | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|<c$b>>%y | LOCK|#Y@^ | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|@$Vr&B | LOCK|y?M | $45B | |||
| Zoetis Inc Class A
ZTS
| LOCK|&BJB%ltt | LOCK|#%Y | $33B | |||
| Viatris Inc
VTRS
| LOCK|Xn%Clc$ | LOCK|ZS | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|@^ | LOCK|vv | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|?%<^pJ | LOCK|z#^ | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|s&%!#& | LOCK|Wp | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|GxN$Gh^ | LOCK|%R>vD | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|Gw@Cwj | LOCK|!m% | $2B |
United States